electroCore, Inc.
NASDAQ:ECOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (6.6), the stock would be worth $3.94 (36% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.3 | $6.15 |
0%
|
| 3-Year Average | 6.6 | $3.94 |
-36%
|
| 5-Year Average | 5.6 | $3.32 |
-46%
|
| Industry Average | 1.9 | $1.14 |
-81%
|
| Country Average | 1.5 | $0.89 |
-86%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
electroCore, Inc.
NASDAQ:ECOR
|
49.2m USD | 10.3 | -3.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 10.9 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 2.2 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 3.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 1.5 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 2.3 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 4.7 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 14.5 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 1.2 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.2 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 4.4 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
